Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT02325674
Recruiting Observational

MEASuRE: Metreleptin Effectiveness And Safety Registry

NCT02325674 · tracked via the Priya Life Science France tracker
Sponsor
Chiesi Farmaceutici S.p.A
Phase
Observational
Started
2016-10-11
Last updated
2026-07-16

Condition(s) studied

Generalised LipodystrophyPartial Lipodystrophy

Investigational drug(s) / intervention(s)

Metreleptin →

Study summary

The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin including, but not limited to, patients in the US and EEA.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients treated with metreleptin through commercial supply at the time or before enrolment into registry * Patients who provide a written consent * Patient coming off metreleptin clinical studies and continuing or restarting treatment with metreleptin through commercial supply Exclusion Criteria: • Patients currently treated with an investigational agent as part of a clinical trial

Primary outcome measure(s)

  • The severity and incidence of the following safety events in patients prescribed Metreleptin in routine clinical practice — Adverse events will be collected from first dose to last visit - min. 10 years. For Prevalent Users: Serious adverse events will be collected from 6 months prior to enrolment to last visit - min. 10 years.
    Estimation of the incidence rates of the following events of special interest in patients treated with metreleptin as part of current clinical practice: acute pancreatitis associated with discontinuation of metreleptin including fatal or necrotizing pancreatitis, hepatic adverse events, severe hypoglycemia, serious hypersensitivity reactions, serious and severe infections resulting in hospitalization or death, loss of efficacy, new diagnoses of autoimmune disorders, autoimmune disease exacerbation, all cancers, exposed pregnancies and pregnancy outcomes, all-cause deaths, medication errors.

Trial sites (28)

FacilityCityRegionStatus
University Alabama at Birmingham Birmingham Alabama Terminated
City of Hope Duarte California Terminated
Atlanta Diabetes Associates Atlanta Georgia Completed
Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois Recruiting
University of Kansas Medical Center Research Institute, Inc. Kansas City Kansas Recruiting
Children's Hospital of New Orleans/LSU Health Sciences Center New Orleans Louisiana Completed
Ochsner Clinic Foundation New Orleans Louisiana Withdrawn
Nih/Niddk/Deob Bethesda Maryland Recruiting
University of Michigan Ann Arbor Michigan Recruiting
Childrens Hospital of Michigan Detroit Michigan Recruiting
Richmond University Medical Centre Staten Island New York Completed
Endocrinology Research Associates Columbus Ohio Recruiting
Children's Hospital of Philadelphia Philadelphia Pennsylvania Recruiting
University of Pennsylvania Philadelphia Pennsylvania Withdrawn
UT Southwestern Medical Center Dallas Texas Recruiting
Seattle Children's Hospital Seattle Washington Recruiting
CHRU Hôpital Claude Huriez Lille Nord Recruiting
Hôpital Robert Debré Paris Paris, France Recruiting
Hôpital Saint-Antoine Paris Paris Recruiting
Universitaetsklinikum Ulm Ulm Baden-Wurttemberg Recruiting
Kinderkrankenhaus Auf der Bult Hanover Lower Saxony Recruiting
Universitaetsklinikum Muenster Münster North Rhine-Westphalia Recruiting
Universitaetsklinikum Leipzig AoeR Leipzig Saxony Recruiting
Alma Mater Studiorum - Università di Bologna Bologna Bologna Recruiting
Azienda Ospedaliero Universitaria Pisana (Presidio di Cisanello) Pisa Pisa Recruiting
Azienda Ospedaliera Universitaria Policlinico Tor Vergata Roma Roma Withdrawn
Universita del Piemonte Orientale "Amedeo Avogadro" Novara Verceilli Recruiting
Addenbrooke's Hospital Cambridge Cambridge Recruiting

More Chiesi Farmaceutici S.p.A. trials in France

A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving Filsuvez Recruiting
A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease Recruiting

Other trials for the same condition

Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02325674 on ClinicalTrials.gov ↗ ← All trials in France